▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #4158 by analyst upside · 2026-09-29
BIO
Bio-Rad Laboratories, Inc.
Healthcare · Market Cap $10B · P/E 46.5x
ANALYST PRICE TARGET
-13.0%
implied upside to consensus target
Current Price $377.69
Consensus Target $328.75
Bull Target $390.0
Bear Target $280.0
Analysts Covering 4
ANALYST CONSENSUS - HOLD
Strong Buy
1
Buy
0
Hold
2
Sell
1
52-Week Low $236.73
52-Week High $396.23
YTD Return +23.7%
FUNDAMENTALS
Market Cap $10B
P/E Ratio (TTM) 46.5x
Forward P/E 37.4x
EPS (TTM) $8.12
PEG Ratio 4.01
Dividend Yield N/A
Revenue (TTM) $2.6B
Profit Margin 8.6%
52-WEEK RANGE
52-Week Low $236.73
52-Week High $396.23
Current Price $377.69
Bear Target $280.0
Bull Target $390.0
● Now $377.69 ● Target $328.75
TRADING DATA
Avg Volume 281K
YTD Return +23.7%
Analyst Count 4
Consensus Hold
Upside to Target -13.0%
Last Updated 2026-09-29

ANALYST SUMMARY

Bio-Rad Laboratories, Inc. (BIO) is currently trading at $377.69 with a Wall Street consensus price target of $328.75, which is 13.0% below the current price over the next 12 months. 4 analysts currently cover BIO, with a consensus rating of Hold - 25% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $390.0, while the most cautious has a target of $280.0.

BIO operates in the Healthcare sector with a market capitalisation of $10B. The stock is up 23.7% year-to-date and is currently trading near the upper end of its 52-week range of $236.73 – $396.23.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

PEN +13.4%
Penumbra, Inc.
$13B · P/E 78.0x · Hold
MEDP -5.5%
Medpace Holdings, Inc.
$17B · P/E 36.4x · Hold
GMAB +10.7%
Genmab A/S
$22B · P/E 28.1x · Buy
ATR +36.7%
AptarGroup, Inc.
$8B · P/E 22.5x · Buy
EXEL -8.0%
Exelixis, Inc.
$14B · P/E 18.3x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for BIO, with each firm's 90-day track record across all stocks we track. See full firm rankings →

RBC Capital - Reiterated
Outperform → Outperform 2026-08-07 Building track record
Citigroup - Reiterated
Neutral → Neutral 2026-08-05 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-08-05 Building track record
Wells Fargo - Reiterated
Equal-Weight → Equal-Weight 2026-08-05 Building track record
Wells Fargo - Reiterated
Equal-Weight → Equal-Weight 2026-05-01 Building track record
Citigroup ↓ Downgrade
Buy → Neutral 2026-04-07 Building track record
Wells Fargo - Reiterated
Equal-Weight → Equal-Weight 2026-02-16 Building track record
Citigroup - Reiterated
Buy → Buy 2025-10-30 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
38
out of 100
Coverage depth
12/30
Consensus clarity
24/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →